Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia - PubMed (original) (raw)
Comment
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Neil P Shah et al. Cancer Cell. 2002 Aug.
Free article
Abstract
Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib. Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found. Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding. Distinct mutations conferred varying degrees of imatinib resistance. Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression. Multiple independent mutant clones were detected in a subset of relapsed cases. Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.
Comment on
- Resistance in the land of molecular cancer therapeutics.
Shannon KM. Shannon KM. Cancer Cell. 2002 Aug;2(2):99-102. doi: 10.1016/s1535-6108(02)00101-0. Cancer Cell. 2002. PMID: 12204529 Review.
Similar articles
- Resistance in the land of molecular cancer therapeutics.
Shannon KM. Shannon KM. Cancer Cell. 2002 Aug;2(2):99-102. doi: 10.1016/s1535-6108(02)00101-0. Cancer Cell. 2002. PMID: 12204529 Review. - Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. Hochhaus A, et al. Leukemia. 2002 Nov;16(11):2190-6. doi: 10.1038/sj.leu.2402741. Leukemia. 2002. PMID: 12399961 Clinical Trial. - BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R. Elias MH, et al. Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6. Leuk Res. 2014. PMID: 24456693 - Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC. Marcé S, et al. Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22. Med Clin (Barc). 2013. PMID: 23433665 - Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
Nardi V, Azam M, Daley GQ. Nardi V, et al. Curr Opin Hematol. 2004 Jan;11(1):35-43. doi: 10.1097/00062752-200401000-00006. Curr Opin Hematol. 2004. PMID: 14676625 Review.
Cited by
- BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India.
S A, Shah A, Ashish A, Kumar Singh N, Kaur M, Kumar Yadav A, Singh R. S A, et al. Leuk Res Rep. 2023 Dec 24;21:100403. doi: 10.1016/j.lrr.2023.100403. eCollection 2024. Leuk Res Rep. 2023. PMID: 39035746 Free PMC article. - Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance.
Okamoto N, Yagi K, Imawaka S, Takaoka M, Aizawa F, Niimura T, Goda M, Miyata K, Kawada K, Izawa-Ishizawa Y, Sakaguchi S, Ishizawa K. Okamoto N, et al. Pharmacol Res Perspect. 2024 Aug;12(4):e1214. doi: 10.1002/prp2.1214. Pharmacol Res Perspect. 2024. PMID: 39031848 Free PMC article. - LncRNA IRAIN overcomes imatinib resistance in chronic myeloid leukemia via NF-κB/CD44 pathway inhibition.
Wang X, Hou Y, Lyu Y, Zhou J, Zhang X, Hassani MA, Huang D, Zhao Z, Zhou D, Xie F, Zhang X, Yan J. Wang X, et al. iScience. 2024 Apr 30;27(6):109851. doi: 10.1016/j.isci.2024.109851. eCollection 2024 Jun 21. iScience. 2024. PMID: 38784023 Free PMC article. - Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection.
Lee CH, Hsu KW, Hsieh YY, Li WT, Long Y, Lin CY, Chen SH. Lee CH, et al. Cells. 2024 Apr 2;13(7):616. doi: 10.3390/cells13070616. Cells. 2024. PMID: 38607055 Free PMC article. - Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.
Wu A, Liu X, Fruhstorfer C, Jiang X. Wu A, et al. Int J Mol Sci. 2024 Mar 14;25(6):3307. doi: 10.3390/ijms25063307. Int J Mol Sci. 2024. PMID: 38542279 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous